10x Genomics Statistics
Total Valuation
10x Genomics has a market cap or net worth of $1.33 billion. The enterprise value is $981.78 million.
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
10x Genomics has 123.13 million shares outstanding. The number of shares has increased by 2.66% in one year.
| Current Share Class | 111.09M |
| Shares Outstanding | 123.13M |
| Shares Change (YoY) | +2.66% |
| Shares Change (QoQ) | +0.83% |
| Owned by Insiders (%) | 8.26% |
| Owned by Institutions (%) | 89.45% |
| Float | 109.01M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.09 |
| Forward PS | 2.25 |
| PB Ratio | 1.88 |
| P/TBV Ratio | 1.93 |
| P/FCF Ratio | 29.29 |
| P/OCF Ratio | 23.42 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.57 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 21.64 |
Financial Position
The company has a current ratio of 5.37, with a Debt / Equity ratio of 0.11.
| Current Ratio | 5.37 |
| Quick Ratio | 4.44 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | 1.77 |
| Interest Coverage | -60,529.67 |
Financial Efficiency
Return on equity (ROE) is -22.03% and return on invested capital (ROIC) is -14.20%.
| Return on Equity (ROE) | -22.03% |
| Return on Assets (ROA) | -12.43% |
| Return on Invested Capital (ROIC) | -14.20% |
| Return on Capital Employed (ROCE) | -22.83% |
| Revenue Per Employee | $478,302 |
| Profits Per Employee | -$120,242 |
| Employee Count | 1,306 |
| Asset Turnover | 0.68 |
| Inventory Turnover | 2.50 |
Taxes
In the past 12 months, 10x Genomics has paid $3.63 million in taxes.
| Income Tax | 3.63M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -45.06% in the last 52 weeks. The beta is 1.98, so 10x Genomics's price volatility has been higher than the market average.
| Beta (5Y) | 1.98 |
| 52-Week Price Change | -45.06% |
| 50-Day Moving Average | 9.02 |
| 200-Day Moving Average | 13.49 |
| Relative Strength Index (RSI) | 62.02 |
| Average Volume (20 Days) | 3,843,489 |
Short Selling Information
The latest short interest is 16.02 million, so 13.01% of the outstanding shares have been sold short.
| Short Interest | 16.02M |
| Short Previous Month | 14.88M |
| Short % of Shares Out | 13.01% |
| Short % of Float | 14.69% |
| Short Ratio (days to cover) | 4.44 |
Income Statement
In the last 12 months, 10x Genomics had revenue of $624.66 million and -$157.04 million in losses. Loss per share was -$1.30.
| Revenue | 624.66M |
| Gross Profit | 427.01M |
| Operating Income | -181.59M |
| Pretax Income | -233.22M |
| Net Income | -157.04M |
| EBITDA | -146.88M |
| EBIT | -181.59M |
| Loss Per Share | -$1.30 |
Full Income StatementBalance Sheet
The company has $426.91 million in cash and $80.07 million in debt, giving a net cash position of $346.83 million or $2.82 per share.
| Cash & Cash Equivalents | 426.91M |
| Total Debt | 80.07M |
| Net Cash | 346.83M |
| Net Cash Per Share | $2.82 |
| Equity (Book Value) | 706.90M |
| Book Value Per Share | 5.74 |
| Working Capital | 471.83M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $56.74 million and capital expenditures -$11.38 million, giving a free cash flow of $45.36 million.
| Operating Cash Flow | 56.74M |
| Capital Expenditures | -11.38M |
| Free Cash Flow | 45.36M |
| FCF Per Share | $0.37 |
Full Cash Flow StatementMargins
Gross margin is 68.36%, with operating and profit margins of -29.07% and -25.14%.
| Gross Margin | 68.36% |
| Operating Margin | -29.07% |
| Pretax Margin | -24.56% |
| Profit Margin | -25.14% |
| EBITDA Margin | -23.51% |
| EBIT Margin | -29.07% |
| FCF Margin | 7.26% |
Dividends & Yields
10x Genomics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.66% |
| Shareholder Yield | -2.66% |
| Earnings Yield | -11.82% |
| FCF Yield | 3.41% |
Dividend DetailsAnalyst Forecast
The average price target for 10x Genomics is $15.81, which is 46.53% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.81 |
| Price Target Difference | 46.53% |
| Analyst Consensus | Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (5Y) | 4.35% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
10x Genomics has an Altman Z-Score of 5.27 and a Piotroski F-Score of 5.
| Altman Z-Score | 5.27 |
| Piotroski F-Score | 5 |